Data on Merck KGaA's L-BLP25

Zacks

Merck KGaA ( '>MKGAF )  recently presented detailed results on its oncology candidate L-BLP25, from the phase III study, START (Stimulating Targeted Antigenic Responses To NSCLC). Results from this study were initially presented in Dec 2012.

L-BLP25 failed to meet its primary endpoint of overall survival in the multi-center, randomized, double-blind, placebo-controlled study conducted in patients with locally advanced stage III non-small cell lung cancer (:NSCLC).

The median overall survival was 25.6 months for L-BLP25 compared with 22.3 months for placebo.

However, treatment effects were seen in certain subgroups. In a predefined subgroup of patients who received concurrent chemoradiotherapy (CRT), the median overall survival was 30.8 months for L-BLP25 compared with 20.6 months for placebo.

Injection site reactions were seen in 17.3% in L-BLP25 versus 11.9% in placebo. Flu-like symptoms were seen in 10.9% in L-BLP25 versus 9.9% in placebo. Potential immune-related diseases were similar for both groups.

Merck KGaA had in-licensed worldwide exclusive rights for L-BLP25 from Oncothyreon Inc (ONTY).

Data from the START study will be presented at the annual meeting of the American Society of Clinical Oncology (TATD). Currently, a second phase III trial, INSPIRE, is being conducted with L-BLP25. The trial is evaluating L-BLP25 in Asian patients suffering from unresectable, stage IIIA or IIIB NSCLC who have had a response or stable disease after at least two cycles of platinum-based CRT.

Merck KGaA carries a Zacks Rank #3 (Hold). Currently, companies like Santarus, Inc. (SNTS) and Salix Pharmaceuticals Ltd. (SLXP) look moreattractive with a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on SNTS

Read the Full Research Report on MKGAF

Read the Full Research Report on SLXP

Read the Full Research Report on ONTY

Zacks Investment Research



More From Zacks.com

Rates

View Comments (1)